D'Adamio Anthony 4

What Happened

• Anthony D'Adamio, SVP & General Counsel of Bioventus (BVS), exercised/converted 17,636 derivative awards (8,886 and 8,750 shares) on March 13, 2026 and, to satisfy tax withholding, 7,663 shares were disposed (sold) at $8.62 per share for total proceeds of $66,055 (two disposals: $33,282 and $32,773). The filing also reports multiple prior and concurrent grants of RSUs/options: two grants on March 14, 2025 (35,000 and 40,000 RSUs) and two grants on March 13, 2026 (83,000 and 92,000 RSUs/options), plus an earlier grant of 35,545 RSUs.

Key Details

• Transaction dates and prices:
  • 2026-03-13: Exercise/conversion of 8,886 and 8,750 derivative units (codes M).
  • 2026-03-13: Withholding/sale of 3,861 and 3,802 shares at $8.62 each (codes F) to cover tax liabilities; combined proceeds $66,055.
  • Grants reported: 2025-03-14 (35,000; 40,000 RSUs) and 2026-03-13 (83,000; 92,000 RSUs/options).
• Shares owned after transaction: not specified in the Form 4 provided.
• Notable footnotes:
  • F1: Each RSU converts to one share of Class A common stock when settled.
  • F2–F3: The 2025 and 2026 RSU/option grants vest in four equal annual installments beginning March 15, 2025 and March 15, 2026, respectively, subject to continued service.
  • F4: An earlier grant of 35,545 RSUs vests in approximately equal annual installments beginning March 14, 2023.
• Filing timing: Form filed March 17, 2026 reporting March 13, 2026 transactions — outside the usual two-business-day window for Form 4s, so this appears to be a late filing.

Context

• The disposals were tax-withholding actions (code F), not open-market selling for investment reasons; this is routine when shares are issued on exercise/settlement and the company withholds or sells shares to satisfy tax obligations.
• The reported A (award/grant) entries are RSUs/options that vest over time; they are not immediate purchases and do not by themselves signal a buy or sell sentiment.